Eicosanoids_NNS
in_IN
breast_NN
cancer_NN
patients_NNS
before_IN
and_CC
after_IN
mastectomy_NN
._.

In_IN
19_CD
patients_NNS
with_IN
a_DT
malignant_JJ
breast_NN
tumor_NN
,_,
tumor_NN
tissue_NN
and_CC
blood_NN
were_VBD
taken_VBN
to_TO
determine_VB
the_DT
eicosanoid_NN
profile_NN
and_CC
platelet_NN
aggregation_NN
._.

Values_NNS
were_VBD
compared_VBN
with_IN
those_DT
of_IN
patients_NNS
with_IN
benign_JJ
tumors_NNS
-LRB-_-LRB-
n_NN
=_JJ
4_CD
-RRB-_-RRB-
,_,
or_CC
undergoing_VBG
a_DT
mammary_JJ
reduction_NN
-LRB-_-LRB-
n_NN
=_JJ
7_CD
-RRB-_-RRB-
._.

Postoperatively_RB
,_,
blood_NN
was_VBD
taken_VBN
as_RB
well_RB
in_IN
order_NN
to_TO
compare_VB
pre_JJ
-_JJ
and_CC
postoperative_JJ
values_NNS
._.

Eicosanoids_NNS
were_VBD
measured_VBN
in_IN
peripheral_JJ
blood_NN
monocytes_NNS
and_CC
mammary_JJ
tissue_NN
by_IN
means_NNS
of_IN
HPLC_NN
;_:
furthermore_RB
,_,
TXA2_NN
,_,
6-keto-PGF1_NN
alpha_NN
,_,
and_CC
PGE2_NN
were_VBD
determined_VBN
by_IN
RIA_NN
._.

Differences_NNS
in_IN
pre_JJ
-_JJ
and_CC
postoperative_JJ
values_NNS
of_IN
cancer_NN
patients_NNS
were_VBD
seen_VBN
in_IN
plasma_NN
RIA_NN
values_NNS
:_:
PGE2_NN
and_CC
6-k-PGF1_NN
alpha_NN
were_VBD
significantly_RB
higher_JJR
preoperatively_RB
when_WRB
compared_VBN
with_IN
postoperatively_NN
,_,
however_RB
,_,
such_JJ
differences_NNS
were_VBD
seen_VBN
in_IN
the_DT
control_JJ
groups_NNS
as_RB
well_RB
._.

Compared_VBN
to_TO
benign_JJ
tumor_NN
or_CC
mammary_JJ
reduction_NN
test_NN
material_NN
the_DT
eicosanoid_NN
profile_NN
of_IN
tissue_NN
obtained_VBN
from_IN
malignant_JJ
mammary_JJ
tumors_NNS
showed_VBD
important_JJ
differences_NNS
._.

Except_IN
for_IN
PGF2_NN
alpha_NN
,_,
HHT_NN
and_CC
15-HETE_NN
no_DT
detectable_JJ
quantities_NNS
of_IN
eicosanoids_NNS
were_VBD
found_VBN
in_IN
the_DT
non-tumor_JJ
material_NN
,_,
whereas_IN
in_IN
the_DT
malignant_JJ
tumor_NN
material_NN
substantial_JJ
quantities_NNS
of_IN
a_DT
number_NN
of_IN
eicosanoid_NN
metabolites_NNS
were_VBD
present_JJ
._.

Statistically_RB
significant_JJ
correlations_NNS
could_MD
be_VB
established_VBN
between_IN
patient\/histopathology_NN
data_NNS
and_CC
the_DT
results_NNS
of_IN
the_DT
platelet_NN
aggregation_NN
assays_NNS
,_,
e.g._FW
between_IN
menopausal_JJ
status_NN
and_CC
ADP_NN
aggregation_NN
;_:
estrogen_NN
receptor_NN
-LRB-_-LRB-
+_CD
\/_:
-_CD
-RRB-_-RRB-
and_CC
collagen_NN
and_CC
arachidonic_JJ
acid_NN
aggregation_NN
,_,
inflammatory_JJ
cell_NN
infiltration_NN
score_NN
and_CC
arachidonic_JJ
acid_NN
aggregation_NN
and_CC
fibrosis_NN
score_NN
and_CC
ADP_NN
aggregation_NN
._.

The_DT
results_NNS
show_VBP
that_IN
eicosanoid_NN
synthesis_NN
in_IN
material_NN
from_IN
mammary_JJ
cancer_NN
patients_NNS
is_VBZ
different_JJ
from_IN
that_DT
in_IN
benign_JJ
mammary_JJ
tissue_NN
._.

The_DT
implications_NNS
,_,
in_IN
particular_JJ
,_,
in_IN
relation_NN
to_TO
future_JJ
prognosis_NN
of_IN
the_DT
patient_NN
,_,
remain_VBP
obscure_JJ
._.

